Challenges and Opportunities With Oncology Drug Development in China-Reference-Cited by-同舟云学术

Challenges and Opportunities With Oncology Drug Development in China

Published:2018-03-08 Issue:2 Volume:105 Page:363-375
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Bajaj Gaurav¹,Gupta Manish¹,Wang Hwei‐Gene Heidi²,Barrett Jeffrey S.³,Tan Matthew²,Rupalla Katrin²,Bertz Richard¹,Sheng Jennifer¹

Affiliation:

1. Bristol‐Myers Squibb, Princeton New Jersey USA

2. Bristol‐Myers SquibbShanghai China

3. Sanofi PasteurSwiftwater Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1017

Reference89 articles.

1. Cancer drug development in China: recent advances and future challenges

2. Cancer statistics in China, 2015

3. Cancer survival in China, 2003-2005: A population-based study

4. Ferlay J.et al.GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide. International Agency for Research on Cancer (IARC) CancerBase No. 11. Lyon France. (2012). Accessed 5 July2017.

5. Challenges to effective cancer control in China, India, and Russia

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020;The Lancet Regional Health - Western Pacific;2024-04

2. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03

3. Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment;International Journal of Ophthalmology;2024-01-18

4. Bridging the new drug access gap between China and the United States and its related policies;Frontiers in Pharmacology;2024-01-08

5. Characteristics of clinical trials of new oncology drugs approved in China;Cancer;2023-11-20